115 related articles for article (PubMed ID: 24183066)
1. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
2. Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.
Ohri N; Werner-Wasik M; Grills IS; Belderbos J; Hope A; Yan D; Kestin LL; Guckenberger M; Sonke JJ; Bissonnette JP; Xiao Y
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e379-84. PubMed ID: 22999272
[TBL] [Abstract][Full Text] [Related]
3. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
[TBL] [Abstract][Full Text] [Related]
4. Impact of Maximum Point Dose Within the Planning Target Volume on Local Control of Nonsmall Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.
Braschi EL; Morris CG; Yeung AR; De Leo AN
Am J Clin Oncol; 2024 May; 47(5):217-222. PubMed ID: 38148589
[TBL] [Abstract][Full Text] [Related]
5. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E
Christ SM; Alongi F; Ricardi U; Scorsetti M; Livi L; Balermpas P; Lievens Y; Braam P; Jereczek-Fossa BA; Stellamans K; Ratosa I; Widder J; Peulen H; Dirix P; Bral S; Ramella S; Hemmatazad H; Khanfir K; Geets X; Jeene P; Zilli T; Fournier B; Ivaldi GB; Clementel E; Fortpied C; Oppong FB; Ost P; Guckenberger M
Radiother Oncol; 2024 Jun; 195():110235. PubMed ID: 38508239
[TBL] [Abstract][Full Text] [Related]
6. Differences in rates of radiation-induced true and false rib fractures after stereotactic body radiation therapy for Stage I primary lung cancer.
Miura H; Inoue T; Shiomi H; Oh RJ
J Radiat Res; 2015 Mar; 56(2):332-7. PubMed ID: 25504640
[TBL] [Abstract][Full Text] [Related]
7. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma.
Liu F; Brown DR; Munley MT
Radiother Oncol; 2024 May; 194():110223. PubMed ID: 38467342
[TBL] [Abstract][Full Text] [Related]
8. Biologically effective dose (BED) value lower than 120 Gy improve outcomes in lung SBRT.
Jimenez-Jimenez E; Marti-Laosa MM; Nieto-Guerrero JM; Perez ME; Gómez M; Lozano E; Sabater S
Clin Transl Oncol; 2024 May; 26(5):1203-1208. PubMed ID: 38017238
[TBL] [Abstract][Full Text] [Related]
9. Modeling of the resensitization effect on carbon-ion radiotherapy for stage I non-small cell lung cancer.
Inaniwa T; Kanematsu N; Nakajima M
Phys Med Biol; 2024 May; 69(10):. PubMed ID: 38604184
[No Abstract] [Full Text] [Related]
10. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results.
Baba F; Shibamoto Y; Tomita N; Ikeya-Hashizume C; Oda K; Ayakawa S; Ogino H; Sugie C
Radiat Oncol; 2009 May; 4():15. PubMed ID: 19476628
[TBL] [Abstract][Full Text] [Related]
11. Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience.
Lucia F; Mievis C; Jansen N; Duysinx B; Cousin F; Louis T; Baiwir M; Ernst C; Wonner M; Hustinx R; Lovinfosse P; Coucke P
Clin Transl Radiat Oncol; 2024 Mar; 45():100720. PubMed ID: 38288310
[TBL] [Abstract][Full Text] [Related]
12. Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
Anderson JD; Hu J; Li J; Schild SE; Fatyga M
J Cancer Ther; 2021 Jul; 12(7):409-423. PubMed ID: 34367717
[TBL] [Abstract][Full Text] [Related]
13. Lung Stereotactic Body Radiation Therapy.
Rehman S; Roach MC; Bradley JD; Robinson CG
Mo Med; 2015; 112(5):361-5. PubMed ID: 26606817
[TBL] [Abstract][Full Text] [Related]
14. Local control of 1-5 fraction radiotherapy regimens for spinal metastases: an analysis of the impacts of biologically effective dose and primary histology.
Kowalchuk RO; Cousins D; Spencer KM; Richardson KM; Larner JM; Showalter TN; McAllister WH; Sheehan JP; Kersh CR; Dutta SW
Rep Pract Oncol Radiother; 2021; 26(6):883-891. PubMed ID: 34992859
[TBL] [Abstract][Full Text] [Related]
15. Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Wu TC; Lee A; Suh R; Oughourlian TC; Abtin F; Hagio MA; Park SJ; Chang AJ; Moghanaki D
J Contemp Brachytherapy; 2024 Apr; 16(2):150-155. PubMed ID: 38808204
[TBL] [Abstract][Full Text] [Related]
16. The Dose/Fractionation Debate in Limited-Stage Small Cell Lung Cancer.
Du K; Liao X; Kishi K
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791986
[TBL] [Abstract][Full Text] [Related]
17. Generality Assessment of a Model Considering Heterogeneous Cancer Cells for Predicting Tumor Control Probability for Stereotactic Body Radiation Therapy Against Non-Small Cell Lung Cancer.
Saga R; Matsuya Y; Obara H; Komai F; Yoshino H; Aoki M; Hosokawa Y
Adv Radiat Oncol; 2024 Apr; 9(4):101437. PubMed ID: 38778820
[TBL] [Abstract][Full Text] [Related]
18. Simulating the Potential of Model-Based Individualized Prescriptions for Ultracentral Lung Tumors.
Chen I; Iyer A; Thor M; Wu AJ; Apte A; Rimner A; Gomez D; Deasy JO; Jackson A
Adv Radiat Oncol; 2023; 8(6):101285. PubMed ID: 38047220
[TBL] [Abstract][Full Text] [Related]
19. Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence.
Davey A; Thor M; van Herk M; Faivre-Finn C; Rimner A; Deasy JO; McWilliam A
Front Oncol; 2023; 13():1156389. PubMed ID: 37503315
[TBL] [Abstract][Full Text] [Related]
20. Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy.
Dajani S; Hill VB; Kalapurakal JA; Horbinski CM; Nesbit EG; Sachdev S; Yalamanchili A; Thomas TO
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
